Goldman Sachs Group Inc Protalix Bio Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 102,178 shares of PLX stock, worth $245,227. This represents 0.0% of its overall portfolio holdings.

Number of Shares

102,178

Previous 289,461 64.7%

Holding current value

$245,227

Previous $741,000 79.62%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.35 - $3.07 $252,832 - $574,958	-187,283 Reduced 64.7%	102,178 $151,000
Q1 2025 May 09, 2025	BUY	$1.88 - $2.69 $450,731 - $644,930	239,751 Added 482.3%	289,461 $741,000
Q4 2024 Feb 11, 2025	SELL	$0.99 - $1.92 $525 - $1,019	-531 Reduced 1.06%	49,710 $95,000
Q3 2024 Nov 14, 2024	SELL	$0.9 - $1.17 $370,545 - $481,708	-411,717 Reduced 89.12%	50,241 $51,000
Q2 2024 Aug 13, 2024	BUY	$1.1 - $1.32 $406,487 - $487,784	369,534 Added 399.82%	461,958 $540,000
Q1 2024 May 15, 2024	SELL	$1.22 - $1.82 $14,703 - $21,934	-12,052 Reduced 11.54%	92,424 $116,000
Q4 2023 Feb 13, 2024	SELL	$1.34 - $1.85 $4,447 - $6,140	-3,319 Reduced 3.08%	104,476 $185,000
Q3 2023 May 14, 2024	BUY	$1.49 - $2.02 $4,945 - $6,704	3,319 Added 3.18%	107,795 $178,000
Q3 2023 Nov 14, 2023	BUY	$1.49 - $2.02 $85,825 - $116,354	57,601 Added 114.76%	107,795 $178,000
Q2 2023 May 14, 2024	SELL	$2.0 - $3.36 $108,564 - $182,387	-54,282 Reduced 51.96%	50,194 $100,000
Q2 2023 Aug 14, 2023	BUY	$2.0 - $3.36 $100,388 - $168,651	50,194 New	50,194 $100,000

Others Institutions Holding PLX

# of Institutions

Shares Held

8.72M

Call Options Held

168K

Put Options Held

31.4K

View Full List

About Protalix BioTherapeutics, Inc.

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $119M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

More about PLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Protalix Bio Therapeutics, Inc. Transaction History